STOCK TITAN

Geron Corp - GERN STOCK NEWS

Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.

Overview

Geron Corp (GERN) is a clinical-stage biopharmaceutical company committed to pioneering innovative therapies in the field of oncology. At the heart of its research is the development of first-in-class telomerase inhibitors, which target the underlying cellular mechanism that enables cancer cells to maintain telomere length—a key factor that contributes to their unchecked replication. This advanced approach positions Geron as a focused innovator within the broad landscape of cancer treatment development, emphasizing a precision-driven strategy that seeks to fundamentally alter how hematologic cancers are managed.

Core Business and Therapeutic Focus

The company’s main product candidate, imetelstat, is a potent, specific inhibitor designed to disrupt telomerase activity. This mechanism is central to the survival and proliferation of cancer cells, particularly in hematologic malignancies. By inhibiting telomerase, imetelstat potentially restricts the limitless division of malignant cells, thereby offering a novel therapeutic pathway for conditions such as myelodysplastic syndromes and myelofibrosis. The clinical-stage exploration of imetelstat underscores Geron Corp's commitment to transforming cancer treatment protocols and deepening our understanding of oncology therapy.

Revenue Model and Corporate Strategy

Geron Corp operates with a revenue model rooted in strategic collaborations within the pharmaceutical and biotechnology sectors. The company leverages licensing agreements, milestone-based payments, and royalty structures to support its research and operational endeavors. This multifaceted approach not only diversifies the financial underpinnings of its business strategy but also reinforces its role as an essential contributor to the oncology therapeutic landscape.

Industry Position and Research Emphasis

Within the competitive framework of biopharmaceutical research, Geron distinguishes itself by focusing exclusively on the development of innovative cancer therapies. Its research-driven approach is underscored by rigorous clinical studies and a deep understanding of the molecular biology of cancer. The company is positioned among specialized entities that are exploring targeted treatment options, relying on sophisticated scientific methodologies to bridge the gap between research innovations and practical, clinical applications.

Scientific and Clinical Expertise

Geron Corp marries scientific inquiry with clinical application through its emphasis on personalized and mechanism-based approaches in treating cancer. Its efforts in developing imetelstat represent a blend of cutting-edge research and meticulous clinical evaluation, providing insights into the potential of telomerase inhibition as a therapeutic modality. By prioritizing expert analysis over speculative claims, Geron consistently communicates an evidence-based narrative that underpins its clinical trials and strategic partnerships.

Operational and Strategic Highlights

  • Innovative Mechanism of Action: The focus on telomerase inhibition addresses a fundamental aspect of cancer cell immortality, offering a concrete rationale behind the therapeutic potential of imetelstat.
  • Focused Clinical Applications: With a targeted approach to hematologic malignancies, Geron becomes a key player in the niche area of blood cancer therapies.
  • Strategic Collaborations: Revenue generation through partnerships and licensing highlights the company’s integrated approach to research, development, and commercial strategy.
  • Scientific Rigor: The company’s operations are underpinned by robust clinical research, embodying the principles of precise and evidence-based innovation in oncology.

Conclusion

In summary, Geron Corp represents a paradigm of focused research and development within the biopharmaceutical industry. Its innovative approach to cancer treatment, primarily through the development of a first-in-class telomerase inhibitor, underscores its commitment to addressing complex oncological challenges through scientific precision and clinical expertise. This detailed exploration helps investors, analysts, and industry watchers gain a nuanced understanding of Geron Corp’s operations, setting a clear context for its role in the evolving landscape of cancer therapeutics.

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN), a biopharmaceutical firm specializing in hematologic malignancies, announced that Dr. John A. Scarlett will present a company overview at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 p.m. ET. The presentation will be available via a live webcast on Geron's Investor Relations website and archived for 30 days thereafter. Geron is currently conducting two Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and refractory myelofibrosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences
-
News
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) reported strong evidence of imetelstat's disease-modifying activity, targeting lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key insights were presented at an Investor Event, highlighting significant unmet needs in these conditions. Geron plans three new clinical programs for imetelstat, including combinations with existing therapies, and anticipates peak revenue exceeding $3 billion in these indications. Financially, Geron reported a net loss of $26.7 million for Q3 2021, with cash reserves of $215.8 million expected to fund operations through early 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
Rhea-AI Summary
Geron Corporation announces that three abstracts related to imetelstat have been accepted as poster presentations at the 63rd American Society of Hematology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) has announced that imetelstat, their first-in-class telomerase inhibitor, has received the Innovation Passport designation from the UK's MHRA under the Innovative Licensing and Access Pathway. This designation aims to expedite the regulatory review process, allowing a 150-day accelerated assessment for Marketing Authorization Applications. The IMerge Phase 2 study demonstrated durable transfusion independence in lower risk MDS patients. Geron is conducting two ongoing Phase 3 clinical trials for imetelstat.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
-
Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) announced the granting of non-statutory stock options for 80,000 shares to new employees as an inducement to join the company. These options were issued on October 20, 2021, at an exercise price of $1.45 per share, matching the closing stock price on that date. The options have a 10-year term and will vest over four years. Geron is focused on developing a telomerase inhibitor, imetelstat, currently in two Phase 3 clinical trials for myeloid hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

Geron Corporation has completed patient enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). Top-line results are anticipated in January 2023. Imetelstat, a first-in-class telomerase inhibitor, has shown promising results in Phase 2 trials, including durable transfusion independence in patients. The IMerge trial involves approximately 170 patients and aims to evaluate red blood cell transfusion independence. The company aims to address the significant medical need for alternative treatments in lower risk MDS patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will hold a virtual investor event on November 9 at 4:00 p.m. ET. The event will address unmet medical needs in lower risk myelodysplastic syndromes and refractory myelofibrosis, focusing on the potential of imetelstat, Geron's first-in-class telomerase inhibitor. Attendees will hear about expansion opportunities for imetelstat and can participate in a live Q&A with experts, including Dr. Swaminathan Iyer and Dr. John Mascarenhas. A webcast will be available on Geron's Investor Relations page, archived for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
-
Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) reported significant findings from its IMbark Phase 2 clinical trial for imetelstat, a treatment for refractory myelofibrosis (MF). Published in the Annals of Hematology, the study indicates that patients treated with imetelstat had a median overall survival (OS) of approximately 30 months, over double the 12 months for those receiving best available therapy. The ongoing IMpactMF Phase 3 trial aims to further validate these results. Imetelstat is noted for its potential to address unmet needs in patients unresponsive to JAK inhibitors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
-
Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) announced the granting of a non-statutory stock option for 400,000 shares of common stock to a newly hired employee. The option was awarded on September 15, 2021 with an exercise price of $1.36, matching the stock's closing price on that date. The option has a 10-year term, vesting in increments over four years, with 12.5% vesting after six months. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aligns with Geron’s 2018 Inducement Award Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) announced that Dr. John A. Scarlett, its Chairman and CEO, will present at three upcoming investor conferences in September 2021. The presentations include the H.C. Wainwright 23rd Annual Global Virtual Investment Conference on September 13, R.W. Baird 2021 Virtual Global Healthcare Conference on September 14, and Cantor Virtual Global Healthcare Conference on September 30. Live webcasts of the presentations will be available through Geron's Investor Relations webpage, with archived replays for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none

FAQ

What is the current stock price of Geron (GERN)?

The current stock price of Geron (GERN) is $1.48 as of April 1, 2025.

What is the market cap of Geron (GERN)?

The market cap of Geron (GERN) is approximately 938.7M.

What is Geron Corp's primary focus?

Geron Corp is dedicated to the research and development of innovative cancer therapies, particularly through the use of first-in-class telomerase inhibitors.

How does the company plan to treat cancers?

The company is exploring the use of imetelstat, a potent telomerase inhibitor, to target the cell replication process in hematologic malignancies such as myelodysplastic syndromes and myelofibrosis.

What makes Geron Corp's approach unique?

Geron Corp employs a targeted mechanism-based strategy by inhibiting telomerase, a key enzyme that allows cancer cells limitless replication, thus addressing a fundamental aspect of cancer biology.

How does Geron generate revenue?

The company generates revenue primarily through collaboration agreements, licensing arrangements, milestone payments, and royalties, which support its research and clinical operations.

How is Geron positioned within the oncology research space?

Geron Corp is recognized for its focused research on telomerase inhibition, situating it among specialized entities within the broader oncology and biopharmaceutical sectors.

What therapeutic areas are targeted by imetelstat?

Imetelstat is primarily being developed for hematologic malignancies, with a focus on diseases such as myelodysplastic syndromes and myelofibrosis, where traditional treatment options are limited.
Geron Corp

Nasdaq:GERN

GERN Rankings

GERN Stock Data

938.67M
632.76M
0.1%
78.42%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY